keyword
MENU ▼
Read by QxMD icon Read
search

Valsartan

keyword
https://www.readbyqxmd.com/read/29781736/comparison-of-real-world-effectiveness-between-valsartan-and-non-ras-inhibitor-monotherapy-on-the-incidence-of-new-diabetes-in-chinese-hypertensive-patients-an-electronic-health-recording-system-based-study
#1
Tian Shen, Jiwei Wang, Yingjun Yu, Jinming Yu
This study aimed to compare the real-world effectiveness of valsartan and non renin-angiotensin system (non-RAS) agent monotherapy on the incidence of new on-set diabetes (NOD) in Chinese hypertensive patients. It was based on an electronic Health Recording System database from Minhang District of Shanghai. Hypertensive patients aged ≥18 years continuously taking either valsartan or non-RAS agent monotherapy for >12 months were included. Hazard ratios (HR) of NOD events were estimated using propensity score matching method and multivariate regression...
May 21, 2018: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/29779951/is-the-paradigm-hf-cohort-representative-of-the-real-world-heart-failure-patient-population
#2
Gustavo Rodrigues, António Tralhão, Carlos Aguiar, Pedro Freitas, António Ventosa, Miguel Mendes
INTRODUCTION: A new drug with prognostic impact on heart failure, sacubitril/valsartan, has been introduced in current guidelines. However, randomized trial results can be compromised by lack of representativeness. We aimed to assess the representativeness of the PARADIGM-HF trial in a real-world population of patients with heart failure. METHODS: We reviewed the records of 196 outpatients followed in a heart failure clinic between January 2013 and December 2014...
May 17, 2018: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://www.readbyqxmd.com/read/29777521/an-early-view-of-real-world-patient-response-to-sacubitril-valsartan-a-retrospective-study-of-patients-with-heart-failure-with-reduced-ejection-fraction
#3
Dana Drzayich Antol, Adrianne Waldman Casebeer, Richard W DeClue, Stephen Stemkowski, Patricia A Russo
INTRODUCTION: Sacubitril/valsartan has been established as an effective treatment for heart failure (HF) with reduced ejection fraction based on clinical trial data; however, little is known about its use or impact in real-world practice. METHODS: This study included data from medical and pharmacy claims and medical records review for patients (n = 200) who initiated sacubitril/valsartan between August 2015 and March 2016 preceding issuance of American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) focused update on new pharmacological therapy for HF (May 2016), which included recommendations for sacubitril/valsartan...
May 17, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29776559/angioedema-in-heart-failure-patients-treated-with-sacubitril-valsartan-lcz696-or-enalapril-in-the-paradigm-hf-study
#4
Victor Shi, Michele Senni, Hendrik Streefkerk, Vikas Modgill, Wenchun Zhou, Allen Kaplan
BACKGROUND: PARADIGM-HF demonstrated significant clinical benefits for sacubitril/valsartan (LCZ696, an angiotensin receptor neprilysin inhibitor) versus the angiotensin-converting enzyme inhibitor (ACEI) enalapril in patients with heart failure with reduced ejection fraction. As inhibition of ACE, and co-inhibition of ACE and neprilysin, may increase the risk of angioedema, this was an adverse event of special interest. METHODS: Following sequential enalapril and sacubitril/valsartan run-ins, patients were randomized to twice-daily sacubitril/valsartan 200 mg or enalapril 10 mg...
August 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29775776/the-probable-roles-of-valsartan-in-alleviating-chronic-obstructive-pulmonary-disease-following-co-exposure-to-cold-stress-and-fine-particulate-matter
#5
Jiangtao Liu, Lei Guo, Kai Zhang, Quanquan Song, Qiaozhen Wei, Qin Bian, Tingting Liang, Jingping Niu, Bin Luo
Angiotensin II (ANG II) might play an important role in the co-effects of cold stress and fine particulate matter (PM2.5 ) on chronic obstructive pulmonary disease (COPD). The purpose of this study is to evaluate the roles of valsartan in alleviating COPD following co-exposure to cold stress and PM2.5 . Both the two intervention factors are carried out upon COPD rats with the intervention of valsartan. Blockade of angiotensin receptor by valsartan decreases the levels of malondialdehyde in the normal temperature and tumor necrosis factor-α under cold stress significantly...
May 7, 2018: Environmental Toxicology and Pharmacology
https://www.readbyqxmd.com/read/29771478/the-reverse-remodeling-response-to-sacubitril-valsartan-therapy-in-heart-failure-with-reduced-ejection-fraction
#6
Pieter Martens, Hanne Beliën, Matthias Dupont, Pieter Vandervoort, Wilfried Mullens
BACKGROUND: Major classes of medical therapy for heart failure with reduced ejection fraction (HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan remains unstudied. METHODS: We performed a single-center, prospective assessor-blinded study to determine the reverse remodeling response of sacubitril/valsartan-therapy in HFrEF-patients with a class I-indication (New York heart Association [NYHA]-class II-IV, Left ventricular ejection fraction [LVEF]<35%, optimal dose with Renin-Angiotensin-System-Blocker [RAS-blocker])...
May 17, 2018: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/29761293/stable-but-progressive-nature-of-heart-failure-considerations-for-primary-care-physicians
#7
REVIEW
Inder Anand
Primary care physicians play a significant role in managing heart failure (HF), with the goals of reducing mortality, avoiding hospitalization, and improving patients' quality of life. Most HF-related hospitalizations and deaths occur in patients with New York Heart Association functional class II or III, many of whom are perceived to have stable disease, which often progresses without clinical symptoms due to underlying deleterious effects of neurohormonal imbalance and endothelial dysfunction. Management includes lifestyle changes and stepped pharmacological therapy directed at the four stages of HF, with aggressive uptitration of therapies, including beta-blockers and inhibitors of the renin-angiotensin-aldosterone system...
May 14, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29754651/rationale-and-methods-of-the-prospective-study-of-biomarkers-symptom-improvement-and-ventricular-remodeling-during-sacubitril-valsartan-therapy-for-heart-failure-prove-hf
#8
James L Januzzi, Javed Butler, Emmanuel Fombu, Alan Maisel, Kevin McCague, Ileana L Piña, Margaret F Prescott, Jerome B Riebman, Scott Solomon
BACKGROUND: Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor indicated for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction; however, its mechanism of benefit remains unclear. Biomarkers that are linked to ventricular remodeling, myocardial injury, and fibrosis may provide mechanistic insight and important clinical guidance regarding sacubitril/valsartan use. METHODS: This 52-week, multicenter, open-label, single-arm study is designed to (1) correlate biomarker changes with cardiac remodeling parameters, cardiovascular outcomes, and patient-reported outcome data and (2) determine short- and long-term changes in concentrations of biomarkers related to potential mechanisms of action and effects of sacubitril/valsartan therapy...
May 2018: American Heart Journal
https://www.readbyqxmd.com/read/29749551/angiotensin-ii-inhibits-the-protein-expression-of-zo%C3%A2-1-in-vascular-endothelial-cells-by-downregulating-ve%C3%A2-cadherin
#9
Longbin Liu, Liping Meng, Peng Zhang, Hui Lin, Jufang Chi, Fang Peng, Hangyuan Guo
Angiotensin II (Ang II) is reported to be involved in the development of various cardiovascular diseases by disrupting microvessel permeability, however, the underlying mechanism remains to be elucidated. The present study aimed to investigate the mechanism by which Ang II disrupts microvascular permeability. Rat endothelial cells were subjected to primary culture and identification. Cells in passages 4‑7 were then used for the following experiments. The cells were divided into control, Ang II, and Ang II + valsartan groups, and reverse transcription‑quantitative polymerase chain reaction and western blot analyses were perform to evaluate the expression of zonula occludens‑1 (ZO‑1) and vascular endothelial (VE)‑cadherin in the cells...
May 8, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29748863/repaglinide-irbesartan-drug-interaction-effects-of-slco1b1-polymorphism-on-repaglinide-pharmacokinetics-and-pharmacodynamics-in-chinese-population
#10
Qi Pei, Jun-Yan Liu, Ji-Ye Yin, Guo-Ping Yang, Shi-Kun Liu, Yi Zheng, Pan Xie, Cheng-Xian Guo, Mi Luo, Hong-Hao Zhou, Xi Li, Zhao-Qian Liu
PURPOSE: On account of the potential inhibition of OATP1B1 (organic anion transporting polypeptide) by angiotensin II receptor blockers (ARBs) and the effects of SLCO1B1 (solute carrier organic anion transporter family member) polymorphism, the aim of current study is to assess the impact of ARBs on the pharmacokinetics (PK) and pharmacodynamics (PD) of repaglinide in Chinese healthy volunteers with different SLCO1B1 genotypes. METHODS: The in vitro study was conducted on irbesartan, valsartan, olmesartan, and losartan by using HEK293 cells transfected with OATP1B1...
May 11, 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29748349/independent-prognostic-value-of-serum-soluble-st2-measurements-in-patients-with-heart-failure-and-a-reduced-ejection-fraction-in-the-paradigm-hf-trial-prospective-comparison-of-arni-with-acei-to-determine-impact-on-global-mortality-and-morbidity-in-heart-failure
#11
Eileen O'Meara, Margaret F Prescott, Brian Claggett, Jean L Rouleau, Lu-May Chiang, Scott D Solomon, Milton Packer, John J V McMurray, Michael R Zile
BACKGROUND: Soluble ST2 (sST2) is associated with cardiac remodeling and fibrosis. In chronic heart failure, the predictive value of sST2 has not been evaluated in a model that includes both NT-proBNP (N-terminal pro-B-type natriuretic peptide) and hs-TnT (high-sensitivity cardiac troponin T), in a trial in which treatment had a major impact. Therefore, the effects of treatment on sST2 levels in PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the relationships between sST2 and outcomes, and the prognostic utility of various sST2 partition values were examined...
May 2018: Circulation. Heart Failure
https://www.readbyqxmd.com/read/29746915/cognition-and-dementia-related-adverse-effects-with-sacubitril-valsartan-analysis-of-the-fda-adverse-event-report-system-database
#12
Amichai Perlman, Bruria Hirsh Raccah, Ilan Matok, Mordechai Muszkat
BACKGROUND: As neprilysin is involved in the degradation of amyloid-beta, there is concern the angiotensin-neprilysin inhibitor, sacubitril-valsartan, could increase the risk for dementia. METHODS: We analyzed adverse event cases submitted to the FDA adverse event report system between July 2015 and March 2017. Cognition and dementia related adverse event cases were defined using broad and narrow structured medical queries. RESULTS: During the period evaluated, 9,004 adverse event reports (out of a total of 2,249,479) involved the use of sacubitril-valsartan...
May 7, 2018: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/29746914/cognition-and-dementia-related-adverse-effects-with-sacubitril-valsartan-analysis-of-the-fda-adverse-event-report-system-database
#13
Amichai Perlman, Bruria Hirsh Raccah, Ilan Matok, Mordechai Muszkat
BACKGROUND: As neprilysin is involved in the degradation of amyloid-beta, there is concern the angiotensin-neprilysin inhibitor, sacubitril-valsartan, could increase the risk for dementia. METHODS: We analyzed adverse event cases submitted to the FDA adverse event report system between July 2015 and March 2017. Cognition and dementia related adverse event cases were defined using broad and narrow structured medical queries. RESULTS: During the period evaluated, 9,004 adverse event reports (out of a total of 2,249,479) involved the use of sacubitril-valsartan...
May 7, 2018: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/29746136/relative-activity-factor-raf-based-scaling-of-uptake-clearance-mediated-by-organic-anion-transporting-polypeptide-oatp-1b1-and-oatp1b3-in-human-hepatocytes
#14
Saki Izumi, Yoshitane Nozaki, Hiroyuki Kusuhara, Koichiro Hotta, Toshiki Mochizuki, Takafumi Komori, Kazuya Maeda, Yuichi Sugiyama
In vitro-in vivo extrapolation based on uptake clearance determined in human hepatocytes has been used to predict in vivo hepatic clearance of organic anion transporting polypeptide (OATP) substrates. This study evaluated the relative activity factor (RAF) approach to extrapolate active uptake clearance in transporter-transfected cell systems (CLuptake ) to that in human hepatocyte suspensions (PSinf,act ). RAF values for OATP1B1 and OATP1B3 were determined in two batches of cryopreserved human hepatocytes using estrone-3-sulfate and cholecystokinin octapeptide as reference substrates, respectively...
May 10, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29736887/transfer-behavior-of-the-weakly-acidic-bcs-class-ii-drug-valsartan-from-the-stomach-to-the-small-intestine-during-fasted-and-fed-states
#15
Rania Hamed, Sabreen Hasan Alnadi
The objective of this study was to investigate the transfer behavior of the weakly acidic BCS class II drug valsartan from the stomach to the small intestine during fasted and fed states. An in vitro transfer model previously introduced by Kostewicz et al. (J Pharm Pharmacol 56(1):43-51, 2004) based on a syringe pump and a USP paddle apparatus was used to determine the concentration profiles of valsartan in the small intestine. Donor phases of simulated gastric fluid during fasted (FaSSGF) and fed (FeSSGF) states were used to predisperse Diovan® tablets (160 mg valsartan)...
May 7, 2018: AAPS PharmSciTech
https://www.readbyqxmd.com/read/29733445/effects-of-treatment-with-an-angiotensin-2-receptor-blocker-and-or-vitamin-d3-on-parathyroid-hormone-and-aldosterone-a-randomized-placebo-controlled-trial
#16
Lise Sofie Bislev, Lene Langagergaard Rødbro, Jesper Nørgaard Bech, Erling Bjerregaard Pedersen, Lars Rolighed, Tanja Sikjaer, Lars Rejnmark
OBJECTIVE: Emerging evidence support a positive, bidirectional and clinical relevant interaction between parathyroid hormone (PTH) and the renin-angiotensin-aldosterone-system (RAAS). A beneficial effect of the widely used RAAS inhibitors might include a PTH lowering effect, as high PTH levels may be harmful to cardiovascular health. We aimed to investigate whether PTH levels are lowered by short-term treatment with an angiotensin 2 receptor blocker (valsartan) independently of co-administration of vitamin D3...
May 7, 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29731022/prediabetes
#17
REVIEW
Aditya K Khetan, Sanjay Rajagopalan
The burden of diabetes is expected to rise from 415 million individuals in 2015 to 642 million individuals by 2040. Most individuals pass through a phase of prediabetes before developing full-blown diabetes. Insulin resistance, impaired incretin action, and insulin hypersecretion are central to the pathophysiology of prediabetes. Individuals older than 40 years of age and other high-risk individuals should be screened for diabetes with fasting plasma glucose and/or hemoglobin A1c. For those diagnosed with prediabetes, the goal of treatment should be restoring euglycemia, because there are data showing that restoring normoglycemia during prediabetes and early diabetes can produce lasting remission...
May 2018: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/29720472/predicting-human-clearance-of-oatp-substrates-using-cynomolgus-monkey-in-vitro-in-vivo-scaling-of-hepatic-uptake-clearance
#18
Tom de Bruyn, Ayse Ufuk, Carina Cantrill, Rachel E Kosa, Yi-An Bi, Mark Niosi, Sweta Modi, A David Rodrigues, Larry M Tremaine, Manthena Vs Varma, Aleksandra Galetin, J Brian Houston
This work explores the utility of the cynomolgus monkey as a preclinical model to predict hepatic uptake clearance mediated by organic anion transporting polypeptide (OATP) transporters. Nine OATP substrates (rosuvastatin, pravastatin, repaglinide, fexofenadine, cerivastatin, telmisartan, pitavastatin, bosentan and valsartan) were investigated in plated cynomolgus monkey and human hepatocytes. Total uptake clearance and passive diffusion were measured in vitro from initial rates in the absence and presence of the OATP inhibitor rifamycin SV, respectively...
May 2, 2018: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/29718530/effect-of-lcz696-a-dual-angiotensin-receptor-neprilysin-inhibitor-on-isoproterenol-induced-cardiac-hypertrophy-fibrosis-and-hemodynamic-change-in-rats
#19
Toru Miyoshi, Kazufumi Nakamura, Daiji Miura, Masashi Yoshida, Yukihiro Saito, Satoshi Akagi, Yuko Ohno, Megumi Kondo, Hiroshi Ito
BACKGROUND: Recent clinical studies have shown that treatment with LCZ696, a complex containing the angiotensin receptor blocker valsartan and neprilysin inhibitor sacubitril, improves the prognosis of heart failure patients with a reduced ejection fraction. This study evaluated whether LCZ696 affects left ventricular hypertrophy, fibrosis, and hemodynamics in isoproterenol (ISO)-treated rats compared with valsartan alone. METHODS: Male Wistar rats received subcutaneous saline (n = 10), subcutaneous ISO (2...
May 2, 2018: Cardiology Journal
https://www.readbyqxmd.com/read/29710617/illicit-drugs-and-pharmaceuticals-in-swimming-pool-waters
#20
G Fantuzzi, G Aggazzotti, E Righi, G Predieri, S Castiglioni, F Riva, E Zuccato
The occurrence of illicit drugs (cocaine, opioids, amphetamines and cannabis derivatives), some of their metabolites and 48 pharmaceuticals, was investigated in pool and source waters in ten Italian indoor swimming pools. The samples were analyzed by highperformance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), after solid phase extraction (SPE). Cocaine and its metabolites were found in nine swimming pools, at concentrations from 0.3 to 4.2 ng/L for cocaine, 1.1 to 48.7 ng/L for norcocaine, 0...
April 20, 2018: Science of the Total Environment
keyword
keyword
16092
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"